| Purity: | 99% min |
|---|---|
| Model Number: | CAS NO.:168273-06-1 |
| Brand Name: | NJBN STEROID |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 200-368-4 |
| MF: | C22h21cl3n4o |
| Other Names: | Acomplia |
| CAS No.: | 168273-06-1 |
| Molecular Weight: | 463.79 |
Quick Details
Specifications
Raw White Weight Loss Steroids SR141716 Rimonabant CAS 168273-06-1
Quick Detail :
Product Name: Rimonabant
Synonyms: ACOMPLIA; RIMONABANT; RIMONABANT(ACOMPLIA, SR141716); 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; A 281; Sr 141716
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Product Categories: Weight Loss; SR141716
Physicochemical properties: white or white crystalline powder, soluble in methanol.
Melting point: 230oC~240oC
Loss on drying: ≤0.5%
PH: (10% aqueous solution) 4-7
Heavy metal: ≤10ppm
TLC: only one spot
Content: ≥99.5%
Indications: new diet, quit smoking, hypolipidemic, pharmaceutical raw materials.
Main uses: a new type of medicine, and can be applied to quit smoking.
Usage : Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane
Description :
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking cannabis. Acomplia, along with CB1 receptors, reduces the EC system's over-activity.
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
Function :
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E. U., Mexico, and Brazil.
Rimonabant / Acomplia, Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 endocannabinoid receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
Rimonabant / Acomplia works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
COA :
Hot products :
Quick Detail :
Product Name: Rimonabant
Synonyms: ACOMPLIA; RIMONABANT; RIMONABANT(ACOMPLIA, SR141716); 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidinopyrazole-3-carboxamide; 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide; A 281; Sr 141716
CAS: 168273-06-1
MF: C22H21Cl3N4O
MW: 463.79
Product Categories: Weight Loss; SR141716
Physicochemical properties: white or white crystalline powder, soluble in methanol.
Melting point: 230oC~240oC
Loss on drying: ≤0.5%
PH: (10% aqueous solution) 4-7
Heavy metal: ≤10ppm
TLC: only one spot
Content: ≥99.5%
Indications: new diet, quit smoking, hypolipidemic, pharmaceutical raw materials.
Main uses: a new type of medicine, and can be applied to quit smoking.
Usage : Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane
Description :
Rimonabant / Acomplia selectively blocks the CB1 receptors that are present in the brain and other peripheral organs important in fat/lipid and glucose metabolism, including muscle, gastrointestinal tract, liver and adipose tissue. Basically, it switches off those brain circuits that are responsible for making people hungry while smoking cannabis. Acomplia, along with CB1 receptors, reduces the EC system's over-activity.
Rimonabant / Acomplia is said to have reduced the overall body fat by 10% in one out of three users. Also, it is reported that those users did not gain back more than a kilo over the next two years if the patients remained on Rimonabant. Rimonabant was recommended for those with a BMI of 30 or greater, who were considered obese, and is most successful when combined with exercise and a proper diet.
Function :
Rimonabant / Acomplia is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E. U., Mexico, and Brazil.
Rimonabant / Acomplia, Developed by Sanofi-Aventis, Acomplia (Rimonabant) is a selective CB1 endocannabinoid receptor antagonist. In other words, Rimonabant is intended to promote weight loss by reducing the total number of calories an individual consumes on a daily basis.
Rimonabant / Acomplia works by blocking endogenous cannabinoid from binding to neuronal CB1 receptors. The activation of these receptors by endogenous cannabinoids, such as anadamide, increases an individuals appetite. By blocking the activation of the receptors, appetite suppression may occur.
COA :
| Test Items | Specification | Test Results |
| Description | White crystalline powder | White crystalline powder |
| Identification | IR , UV conform | Conform |
| Loss on drying | ≤0.5ml | 0.21ml |
| Residue on ignition | Not more than 0.2% | 0.06ml |
| Iron | Not more than 0.005% | 0.0018% |
| Heavy metals | Not more than 0.001% | 0.0006% |
| Related substances |
Total: Not more than 1.0% Individual: Not more than 0.5% |
0.32% 0.14% |
| E-isomer | Not more than 0.3% | 0.19% |
| Organic volatile impurities | Conforms | Conforms |
| Assay | 99.0~101.0% | 99.51% |
| Conclusion | Conform with USP30 | |
Hot products :
|
|
Testosterone Enanthate CAS: 315-37-7 Testosterone acetate CAS: 1045-69-8 Testosterone propionate CAS: 57-85-2 Testosterone cypionate CAS: 58-20-8 Testosterone phenylpropionate CAS: 1255-49-8 Testosterone isocaproate CAS: 15262-86-9 Testosterone decanoate CAS: 5721-91-5 Testosterone undecanoate CAS: 5949-44-0 Testosterone Sustanon 250 17-Methyltestosterone CAS: 58-18-4 Turinabol/4-chlorotestosterone acetate CAS: 855-19-6 Oral turinabol CAS: 2446-23-3 |
| METHENOLONE SERIES (Primobolan) |
Methenolone Enanthate CAS: 303-42-4 Methenolone Acetate/Primobolan CAS: 434-05-9 |
| ORAL STEROIDS | Methandrostenolone(Dianabol, metandienone) CAS: 72-63-9 |
| ANTI-ESTROGEN |
Tamoxifen Citrate (Nolvadex) CAS: 54965-24-1 Clomiphene citrate CAS: 50-41-9 Toremifene citrate CAS: 89778-27-8 Letrazole(Femara) CAS: 112809-51-5 Methoxydienone CAS: 2322-77-2 Estradiol CAS: 50-28-2 Norgestrel CAS: 6533-00-2 |
| Weight loss Medicines |
L(-)-Carnitine CAS: 541-15-1 Rimonabant CAS: 168273-06-1 Synephrine CAS: 94-07-5 LORCASERIN CAS: 616202-92-7 Orlistat CAS: 96829-58-2 |
| MALE SEXUAL ENHANCEMENT POWDERS |
Dapoxetine hydrochloride CAS: 129938-20-1 Vardenafil CAS: 224785-91-5 Yohimbine HCl CAS: 65-19-0 Amino Tadalafil CAS: 385769-84-6 |